NCT04669197View on ClinicalTrials.gov

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

December 1, 2020

Primary Completion Date

February 21, 2024

Study Completion Date

December 30, 2025

Conditions
Untreated Resectable Pancreatic AdenocarcinomaBorderline Resectable Pancreatic AdenocarcinomaLocally Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

Paclitaxel protein bound

combination therapy

DRUG

Gemcitabine

combination therapy

DRUG

Cisplatin

combination therapy

DRUG

Hydroxychloroquine

combination therapy

Trial Locations (1)

85258

HonorHealth Research Institute, Scottsdale

Sponsors
All Listed Sponsors
lead

HonorHealth Research Institute

OTHER